A few issues concerning the salicylic acid analogue mentioned in this recent article.
Salicylic acid
- 2-hydroxybenzoic acid (2-HBA)
γ-Resorcylic acid
- 2,6-dihydroxybenzoic acid (2,6-DHBA)
Variations in the additional hydroxyl group relative to salicylic acid (orange):
Hydroxybenzoic acid isomers and the cardiovascular system
The coordination in 2,6-DHBA helps to stabilize the molecule in an ionized state:
Source: the internet.
I think that this property is responsible for its lower pKa, making it a 'stronger' acid, that's more prone to deprotonate (benzoic acid → benzoate⁻ + H⁺) and stay as such.
pKa:
This does make 2,6-DHBA a molecule with greater acidification potential. However, the pH in the body is much higher than needed to ionize them, making the difference irrelevant:
- 50 mmol 2-HBA → 50 H⁺ mmol
- 50 mmol 2,6-DHBA → 50 H⁺ mmol
Once we adjust their doses to match for their alleged potencies and possible risk of toxicity, we may get something like:
- 50 mmol 2-HBA → 50 mmol H⁺
- 5 mmol 2,6-DHBA → 5 mmol H⁺
Which casts doubt on the benefit being from relying on a 'stronger' acid.
To counteract the inverted pH of cancer cells, we have to acidify the interior or alkalinize the exterior. 2,6-DHBA deprotonates already in the stomach, which only adds to the burden of extratumoral acidification. In contrast, I just shared with Jennifer a clinic that infuses baking soda in people with cancer.
Ray's suggestion to manipulate acidity through carbonic anhydrases has more basis. The hydrocarbonate ion recirculates in cancer cells and functions as a carrier of protons, taking them from inside, discharging outside, and repeating the process. Inhibition of carbonic anhydrases compromises this removal of protons and creates an unfavorable environment in cells.
Regarding lipophilicity, the greater the degree of hydroxylation, the less lipophilic a molecule tends to be. It's what happens to venom D when it goes from kilciol to kilcidiol and then to kilcitriol.
Plant-Derived and Dietary Hydroxybenzoic Acids—A Comprehensive Study of Structural, Anti-/Pro-Oxidant, Lipophilic, Antimicrobial, and Cytotoxic Activity in MDA-MB-231 and MCF-7 Cell Lines
"The obtained (experimental and theoretical) logP values for HBAs are in the range 0 < logP < 3; this means that these compounds possess from slightly hydrophilic (logP: 0–1) to moderately lipophilic properties (logP: 1–3) [101]. Generally, the disubstituted hydroxybenzoic acids were more lipophilic than the trisubstituted one (gallic acid has hydrophilic properties, and dissolves well in water and other polar solvents). According to the experimental logP values, the compounds can be ordered by increasing lipophilicity as follows: 3,4,5-THB→3,4-DHB~3,5-DHB→ 2,3-DHB→2,4-DHB →2,5-DHB →2,6-DHB."
"Dissociation and association phenomena affect the value of the partition coefficient. Therefore, we observed a relationship between the acid dissociation constants (expressed as pKa) and the values of partition coefficients. Each functional group that can be a hydrogen bond donor or acceptor increases the hydrophilic nature of the compound. Hydroxyl and carboxylic groups present in the structures of the compounds can form hydrogen bonds with water molecules in the aqueous environment, which affects their solubility in water. Therefore, in the case of 3,4,5-trihydroxybenzoic acid, an increase in the hydrophilic properties of the acid is noticeable. The more hydrogen bonds can be formed between a molecule and water molecules, the greater its solubility in water. In the case of ortho- substituted benzoates, the -OH group in the ortho- position is mostly engaged in hydrogen bond formation with the -COOH group, facilitating dissociation of the H+ carboxylic group and increasing the acidity of 2,6-DHB (pKa = 1.30) and, to a lesser extent, 2,3-DHB (pKa = 2.91), 2,5-DHB (pKa = 2.97), and 2,4-DHB (pKa = 3.11). In the case of 3,5-DHB (pKa = 4.04), 3,4-DHB (pKa = 4.26), and 3,4,5-THB (pKa = 4.40), the -OH groups are too far from -COOH to interact with this functional group, but may form hydrogen bonds with the solvent. As a result, the acidity of these acids decreases (higher values of pKa) compared to the ortho-substituted benzoates."
"The dependency between acidity (pKa exp.) and lipophilicity (logPexp.) in the series of studied hydroxybenzoic acids is shown in Figure 7. With the increase in the acidity of the compounds, the lipophilicity increases as well. Therefore, the hydroxybenzoic acids can be divided into three groups characterized by: (a) lower acidity and lipophilicity (3,4,5-THB; 3,4-DHB; 3,5-DHB), (b) moderate acidity and lipophilicity (2,3-DHB; 2,4-DHB; 2,5-DHB), and (c) higher acidity and lipophilicity (2,6-DHB)."
That's counterintuitive.
But here's the value for salicylic acid:
Lipophilicity Study of Salicylic and Acetylsalicylic Acids Using Both Experimental and Calculations Methods
"Experimental n-octanol-water partition coefficients (logPexp) determined by traditional shake-flask method were equal to 2.35 and 1.14 for salicylic and acetylsalicylic acids, respectively."
Aspirin is 'rapidly deacetylated' in the body, and salicylate is the main circulating metabolite, which must not differ a lot from 2,6-DHBA in terms of lipophilicity.
Aspirin, stroke and drug-drug interactions
They don't include the small intestine in the first-pass effect, when it's also responsible for the presystemic metabolism of the drug.
Acetyl transference appears to be a neutral reaction. But deacetylation through hydrolysis leads to proton release rather than the expected consumption (to reform the hydroxyl group). A proton from a water molecule is taken up by salicylate and the rest complexes with the freed acetyl group, which occurs deprotonated.
Aspirin and salicylate: An old remedy with a new twist
"Aspirin has a short half-life in circulating blood (~20 minutes) and is rapidly deacetylated and converted to salicylate in vivo. Salicylate does not affect COX-1 or COX-2 activity. Thus, the anti-inflammatory and antineoplastic actions of aspirin and salicylate remain a dilemma. Sodium salicylate paradoxically inhibited prostaglandin synthesis when added to intact cells.[7] Furthermore, healthy subjects taking sodium salicylate excreted a significantly lower amount of prostaglandin metabolites in urine than those not taking sodium salicylate, and their levels of inhibition were comparable to those of patients taking aspirin and indomethacin.[9] Aspirin also reduces human seminal prostaglandin levels.[10] These data suggest that salicylate inhibits COX metabolism by a mechanism different from a direct inhibition of COX activity."
So, part of aspirin won't reach the circulation, deacetylation can occur before systemic distribution, and the other part is soon deacetylated. Salicylate level can remain elevated for hours.
That we will be dealing with ionized forms conflicts with lipophilicity.
Effect of Enteric Coating on Antiplatelet Activity of Low-Dose Aspirin in Healthy Volunteers
"Aspirin is deacetylated to inactive salicylate at a number of sites, including the gut; thus, its bioavailability is about 50%. Plain aspirin is absorbed from the stomach, where the low pH protects aspirin against deacetylation and maintains aspirin in a nonionized form which encourages absorption."
The pKa of 2,6-DHBA is low enough that it can remain partially ionized even in the acidic pH of the stomach, which prevents intact absorption in an extreme scenario where gastric cancer cells were the desired target.
Therefore, I don't think that 2,6-DHBA being a 'strong' acid is a good reason to adopt it or a convincing explanation for the positive outcomes of use. Aspirin overdose can indeed result in acidosis, but would be an indirect effect.